在技术不确定条件下对乙肝疫苗研发评价的复合期权法

Evaluating Hepatitis B Vaccine R&D under Technical Uncertainty using Compound Options

本文将多阶段复合期权模型应用于某公司的治疗性乙肝疫苗研发项目中,通过计算本文得出结论:即使在临床Ⅰ期和临床Ⅱ期研发都成功的前提下,该公司也不应该投资该项目。

Finally, the multiple stage compound option models are applied to a company of therapeutic hepatitis B vaccine R&D project. By calculation, we can get the conclusion that even though the clinical stage I and II succeeded, the company should not invest in the project.